Publications by authors named "Francesca Maria Onidi"

Claim this Profile
U
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Francesca Maria Onidi

J Clin Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.
Antonio Tursi, Giammarco Mocci, Francesco Costa, Linda Ceccarelli, Edoardo Savarino, Francesca Maria Onidi

Intest Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Preparation based on Symbiotic Association Between Inulin, FOS, L. rhamnosus GG, Bromelin, Boswellia, Vitamin D3, Quercetin and L-tryptophan in Mild-to-Moderate Ulcerative Colitis: A Pilot Retrospective Multicenter Study.
Giammarco Mocci, Giorgia Orrù, Walter Elisei, Paolo Usai Satta, Francesca Maria Onidi

Rev Recent Clin Trials· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Genetic Characteristics of Pediatric Patients with Inflammatory Bowel Disease Transitioning to Adult Medicine: A Single-Center Ten-Year Experience.
Giammarco Mocci, Giorgia Orrù, Francesca Maria Onidi, Mara Corpino, Antonella Marongiu

J Clin Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study.
Giammarco Mocci, Antonio Tursi, Franco Scaldaferri, Daniele Napolitano, Daniela Pugliese, Francesca Maria Onidi

J Clin Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.
Giammarco Mocci, Antonio Tursi, Francesca Maria Onidi, Paolo Usai-Satta, Giovanni Mario Pes

J Clin Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study.
Antonio Tursi, Giammarco Mocci, Franco Scaldaferri, Daniele Napolitano, Rossella Maresca, Francesca Maria Onidi

Expert Opin Biol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Antonio Tursi, Giammarco Mocci, Linda Cingolani, Edoardo Savarino, Roberta Pica, Francesca Maria Onidi

Expert Opin Pharmacother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Giammarco Mocci, Antonio Tursi, Giovanni Maconi, Giovanni Cataletti, Beatrice Mantia, Francesca Maria Onidi

Expert Opin Biol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study.
Alessandra Guarini, Silvia Biagini, Antonella Capaldi, Daniela Carretto, Anna De Angelis, Francesca Maria Onidi

Ann Gastroenterol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis